IL37 and cancer: In conclusion, the results of this study have highlighted the function of IL-37 in harnessing antitumor immunity through the inactivation of cytotoxic T cells and established a newly defined suppressor IL-37/SIGIRR as a treatment option for CRC in the cancer immune cycle.